| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.14B | -46.9% |
| Gross profit | ¥0.01B | — |
| Operating income | ¥-0.03B | — |
| Net income | ¥-0.03B | — |
| Gross margin | 8.7% | Net margin -21.7% |
| Revenue Q/Q | -57.1% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.13B | 91.3% |
| R&D | ¥0.01B | 6.5% |
| SG&A | ¥0.04B | 26.4% |
| Tax & other | ¥0.00B | 0.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
雪榕生物 ・ 中亚股份 ・ 恒实科技 ・ 友讯达 ・ 三德科技 ・ 久之洋 ・ 海波重科 ・ 新迅达 ・ 新光药业 ・ 科大国创 ・ 爱司凯 ・ 世名科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies